(Reuters) – Eli Lilly and Co reported an 18% fall in fourth-quarter profit on Thursday, hurt by higher drug development expenses.
The company’s net income fell to $1.73 billion, or $1.90 per share, in the fourth quarter ended Dec. 31, from $2.12 billion, or $2.32 per share, a year earlier.
(Reporting by Leroy Leo and Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)
